Evaluation of the effect of autologous adipose-derived stem cells from adipose tissue by flow cytometry for the treatment of androgenetic alopecia

Application of autologous adipose-derived stromal/stem cells isolated from adipose tissue by flow cytometry for the treatment of men with androgenetic alopecia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110731007160N11

Enrollment

Registered

2026-04-28

Start date

2025-10-23

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

androgenetic alopecia. Androgenic alopecia

Interventions

The intervention group consists of SVF cells, prepared in accordance with the guidelines established by the International Federation for Adipose Therapeutics and Science (IFATS) and the International

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Male patients with levels 3 to 5 of androgenetic alopecia

Exclusion criteria

Exclusion criteria: 1- Evidence of sepsis 2- Evidence of immune suppression and cancer 3- Use of anti-AGA pharmaceutical medications (e.g., finasteride, dutasteride, or antiandrogens, minoxidil, prostaglandin analogs, retinoids, or corticosteroids) in the past 12 months

Design outcomes

Primary

Measure	Time frame
1- Measuring the rate of hair growth. by dermatologists visually using a 5-point scale. The conditions include 1 - slight improvement; 2 - moderate improvement; 3 - excellent improvement; 4 - no change; 5 - worsening before and 3 and 6 months after treatment. Timepoint: At the beginning of the study (before the initiation of the intervention), 2 to 3 months after the intervention started, and 3 to 6 months after the intervention was completed. Method of measurement: Visual analogue scale score of the treatment effect by the dermatologist.;- Measuring the rate of hair loss by dermatologists visually using a 5-point scale. The conditions include 1 - slight improvement; 2 - moderate improvement; 3 - excellent improvement; 4 - no change; 5 - worsening before and 3 and 6 months after treatment. Timepoint: At the beginning of the study (before the initiation of the intervention), 2 to 3 months after the intervention started, and 3 to 6 months after the intervention was completed. Method of measurement: Visual analogue scale score of the treatment effect by the dermatologist.	—

Measure

Time frame

1- Measuring the rate of hair growth. by dermatologists visually using a 5-point scale. The conditions include 1 - slight improvement; 2 - moderate improvement; 3 - excellent improvement; 4 - no change; 5 - worsening before and 3 and 6 months after treatment. Timepoint: At the beginning of the study (before the initiation of the intervention), 2 to 3 months after the intervention started, and 3 to 6 months after the intervention was completed. Method of measurement: Visual analogue scale score of the treatment effect by the dermatologist.;- Measuring the rate of hair loss by dermatologists visually using a 5-point scale. The conditions include 1 - slight improvement; 2 - moderate improvement; 3 - excellent improvement; 4 - no change; 5 - worsening before and 3 and 6 months after treatment. Timepoint: At the beginning of the study (before the initiation of the intervention), 2 to 3 months after the intervention started, and 3 to 6 months after the intervention was completed. Method of measurement: Visual analogue scale score of the treatment effect by the dermatologist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Nasrin Hamidizadeh

Shiraz University of Medical Sciences

n.hamidizadeh.mdrc@gmail.com098 71 2125592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026